Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France

BMC Gastroenterology

Nils-Olov Stålhammar²  Nicolas Despiégel¹  Mary Lou Furstnau¹  Magnus Ruth²  Peter Wahlqvist²  Maria Karlsson²  Helena Granstedt Löfman²  Stanislas Bruley des Varannes³ 

[1] OptumInsight, Nanterre, France;AstraZeneca R&D, Mölndal, Sweden;Institut des Maladies de l’Appareil Digestif, University Hospital – CHU Hôtel Dieu, Place A Ricordeau, Nantes Cedex, 44093, France

关键词: Productivity;    Quality of life;    GERD;    PPIs;   

Others  :  858152
DOI  :  10.1186/1471-230X-13-39

 received in 2012-08-22, accepted in 2013-02-21,  发布年份 2013

【 摘 要 】

Background

Gastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD.

Methods

Patients with partial response to PPI therapy, defined as persistent GERD symptoms ≥3 days/week despite optimized treatment with a PPI, were recruited for this 12-month observational study. GERD symptoms, HRQL, work productivity and resource use were assessed by patient surveys. Costs were calculated based on lost work productivity and resource use.

Results

The patient population (n=262; mean age, 54 years; 40% men) carried a significant symptom burden, with 98% of patients having moderate-to-severe GERD symptoms and 65% of patients experiencing daily symptoms at baseline. HRQL and work productivity were significantly impaired, with a greater degree of impairment in patients with higher symptom burden. The mean total cost per patient over the 12-month follow-up period was €5237, of which €4674 (89%) was due to lost work productivity.

Conclusions

Partial response to PPI therapy for GERD is associated with a high symptom burden, significant impairment of HRQL and work productivity, and substantial GERD-related costs.

【 授权许可】

   
2013 des Varannes et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Dent J, El-Serag HB, Wallander MA, Johansson S: Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54(5):710-717.
• [2]Bruley des Varannes S, Marek L, Humeau B, Lecasble M, Colin R: Gastroesophageal reflux disease in primary care. Prevalence, epidemiology and quality of life of patients. Gastroenterol Clin Biol 2006, 30(3):364-370.
• [3]Kahrilas PJ, Shaheen NJ, Vaezi MF: American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008, 135(4):1392-1413.
• [4]El-Serag H, Becher A, Jones R: Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010, 32(6):720-737.
• [5]Stålhammar N-O, Spiegel BM, Granstedt Löfman H, Karlsson M, Wahlqvist P, Næsdal J, Nelson MT, Despiégel N: Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA. Pragmatic Observ Res 2012, 3:57-67.
• [6]Vakil N, Karlsson M, Denison H, Rydén A: A patient reported outcome instrument in partial responders to proton pump inhibitor therapy suggests new symptoms deserve consideration: results from a validation study. Gut 2011, 60(Suppl. 3):A266.
• [7]Shaw MJ, Talley NJ, Beebe TJ, Rockwood T, Carlsson R, Adlis S, Fendrick AM, Jones R, Dent J, Bytzer P: Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001, 96(1):52-57.
• [8]Snaith RP: The hospital anxiety and depression scale. Health Qual Life Outcomes 2003, 1:29. BioMed Central Full Text
• [9]Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30(6):473-483.
• [10]Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33(5):337-343.
• [11]Wahlqvist P, Medin J, Karlsson M, Reilly MC: Responsiveness to change and construct validity of the Work Productivity and Activity Impairment questionnaire for gastroesophageal reflux disease (WPAI:GERD) in Swedish patients. Value Health 2009, 12(3):A60.
• [12]Base des médicaments et informations tarifaires. http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI webcite Accessed 25 March 2013
• [13]Tarifs conventionnels. http://www.ameli.fr/professionnels-de-sante/medecins/votre-convention/tarifs/tarifs-conventionnels-des-medecins-generalistes/tarifs-des-medecins-generalistes-en-metropole.php webcite Accessed 25 March 2013
• [14]Consommation en santé\Activité des professions de santé libérales\Professions médicales\Généralistes libéraux\Dépassements\Valeur moyenne du dépassement. http://www.ecosante.org/index2.php?base=FRAN&langh=FRA&langs=FRA&sessionid= webcite) Accessed 25 March 2013.
• [15]Démographie et honoraires des médecins libéraux en. 2006. http://www.ameli.fr/fileadmin/user_upload/documents/DP_honoraires_2006_def.pdf webcite Accessed 25 March 2013.
• [16]Coût mensuel de la main d’oeuvre (tps00174). http://epp.eurostat.ec.europa.eu/portal/page/portal/labour_market/labour_costs/main_tables webcite Accessed 25 March 2013.
• [17]Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O: Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997, 92(1):37-41.
• [18]Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, Labenz J, Leodolter A, Lind T, Richter K: Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther 2012, 35(1):154-164.
• [19]Kartman B, Gatz G, Johannesson M: Health state utilities in gastroesophageal reflux disease patients with heartburn: a study in Germany and Sweden. Med Decis Making 2004, 24(1):40-52.
• [20]Revicki DA, Wood M, Maton PN, Sorensen S: The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998, 104(3):252-258.
• [21]Wahlqvist P: Symptoms of gastroesophageal reflux disease, perceived productivity, and health-related quality of life. Am J Gastroenterol 2001, 96(8 Suppl):S57-S61.
• [22]Kulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, Lind T, Meyer-Sabellek W, Malfertheiner P, Stolte M: Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease– an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003, 18(8):767-776.
• [23]El-Dika S, Guyatt GH, Armstrong D, Degl’innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten S, Heels-Ansdell D, Wahlqvist P: The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol 2005, 5:23. BioMed Central Full Text
• [24]Pacini F, Calabrese C, Cipolletta L, Valva MD, Russo A, Savarino V, Vigneri S: Burden of illness in Italian patients with gastro-oesophageal reflux disease. Curr Med Res Opin 2005, 21(4):495-502.
• [25]Ronkainen J, Aro P, Storskrubb T, Lind T, Bolling-Sternevald E, Junghard O, Talley NJ, Agreus L: Gastro-oesophageal reflux symptoms and health-related quality of life in the adult general population–the Kalixanda study. Aliment Pharmacol Ther 2006, 23(12):1725-1733.
• [26]Ekesbo R, Sjöstedt S, Sörngård H: Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study. Clin Drug Investig 2011, 31(3):181-189.
• [27]Gisbert JP, Cooper A, Karagiannis D, Hatlebakk J, Agreus L, Jablonowski H, Nuevo J: Impact of gastroesophageal reflux disease on work absenteeism, presenteeism and productivity in daily life: a European observational study. Health Qual Life Outcomes 2009, 7:90. BioMed Central Full Text
• [28]Liker H, Jones R, Ducrotté P: The effect of sleep disturbance due to gastroesophageal reflux disease on work and leisure productivity: results from a multinational survey. Gastroenterology 2005, 128(4 Suppl 2):A386.